NASDAQ:OLMA Olema Pharmaceuticals (OLMA) Stock Price, News & Analysis $7.02 -0.13 (-1.82%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$7.02 0.00 (-0.07%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Olema Pharmaceuticals Stock (NASDAQ:OLMA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Olema Pharmaceuticals alerts:Sign Up Key Stats Today's Range$6.88▼$7.3650-Day Range$6.41▼$10.2952-Week Range$6.24▼$36.26Volume1.26 million shsAverage Volume1.52 million shsMarket Capitalization$614.99 millionP/E RatioN/ADividend YieldN/APrice Target$40.60Consensus RatingModerate Buy Company Overview Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for women’s cancers, particularly breast cancer. The company’s research centers on treatments that target pathways involved in hormone-sensitive tumors. Its lead candidate, palazestrant (OP-1250), is an oral therapy designed to act as both a selective estrogen receptor degrader and a complete estrogen receptor antagonist. Olema has studied it as a potential treatment for estrogen receptor–positive breast cancer, including in combination with other cancer medicines. The company is also developing OP-3136, an investigational candidate targeting KAT6 proteins. Olema does not have marketed products; its work is focused on research and clinical development. The company was founded by Sean Biller, who has served as its chief executive officer.AI Generated. May Contain Errors. Read More Olema Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks26th Percentile Overall ScoreOLMA MarketRank™: 1.320264193365 of 5 starsOlema Pharmaceuticals scored higher than 26% of companies evaluated by MarketBeat, and ranked 746th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingOlema Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on no strong buy ratings, 11 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialOlema Pharmaceuticals has a consensus price target of $40.60, representing about 478.3% upside from its current price of $7.02.Amount of Analyst CoverageOlema Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Olema Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Olema Pharmaceuticals are expected to decrease in the coming year, from ($2.61) to ($3.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Olema Pharmaceuticals is -2.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Olema Pharmaceuticals is -2.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOlema Pharmaceuticals has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted22.38% of the float of Olema Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverOlema Pharmaceuticals has a short interest ratio ("days to cover") of 11.86, which indicates bearish sentiment.Change versus previous monthShort interest in Olema Pharmaceuticals has recently increased by 9.22%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOlema Pharmaceuticals does not currently pay a dividend.Dividend GrowthOlema Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 4 news articles for Olema Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest6 people have searched for OLMA on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Olema Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Olema Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders12.56% of the stock of Olema Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.78% of the stock of Olema Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Olema Pharmaceuticals' insider trading history. Receive OLMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Olema Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OLMA Stock News HeadlinesOlema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR SymposiumNovember 18, 2026 | globenewswire.comTranscript : Olema Pharmaceuticals, Inc. Presents at UBS Global Biopharma Conference 2026, Nov-17-2026 03:20 PMNovember 17, 2026 | marketscreener.comMPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access for just $7. The specialized indicator shows when a stock is likely to "snap back," helping traders avoid buying at the peak. It can also flag when a stock may bounce off the bottom so you can time your entry. Run NVDA or any other popular AI stock through it before you place a trade.November 22 at 1:00 AM | Base Camp Trading (Ad)Olema Oncology, Inc. (OLMA) Olema Pharmaceuticals, Inc. Presents at UBS Global Biopharma Conference 2026 TranscriptNovember 17, 2026 | seekingalpha.comOlema Oncology to Participate in Upcoming Investor ConferencesNovember 16, 2026 | globenewswire.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock Has Consensus Price Target of $40.60November 13, 2026 | americanbankingnews.comTranscript : Olema Pharmaceuticals, Inc. Presents at Stifel 2026 Healthcare Conference 2026, Nov-11-2026 10:40 AMNovember 12, 2026 | marketscreener.comMOlema Pharmaceuticals, Inc. (OLMA) Presents at Stifel 2026 Healthcare Conference 2026 TranscriptNovember 12, 2026 | seekingalpha.comSee More Headlines OLMA Stock Analysis - Frequently Asked Questions How have OLMA shares performed this year? Olema Pharmaceuticals' stock was trading at $25.00 at the beginning of 2026. Since then, OLMA shares have decreased by 71.9% and is now trading at $7.02. How were Olema Pharmaceuticals' earnings last quarter? Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) posted its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by $0.09. When did Olema Pharmaceuticals IPO? Olema Pharmaceuticals (OLMA) raised $187 million in an initial public offering on Thursday, November 19th 2020. The company issued 11,000,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Cowen and Canaccord Genuity acted as the underwriters for the IPO. Who are Olema Pharmaceuticals' major shareholders? Top institutional investors of Olema Pharmaceuticals include State Street Corp (4.40%), Goldman Sachs Group Inc. (1.70%), Candriam S.C.A. (1.35%) and Algert Global LLC (0.72%). Insiders that own company stock include Bain Capital Life Sciences Inv, Biocapital Advisors L Paradigm, Cyrus Harmon, David C Myles, Sean Bohen, Shane William Charles Kovacs, Naseem Zojwalla, Shawnte Mitchell and Ian T Clark. View institutional ownership trends. How do I buy shares of Olema Pharmaceuticals? Shares of OLMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Olema Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Olema Pharmaceuticals investors own include NVIDIA (NVDA), Symbotic (SYM), Voyager Therapeutics (VYGR), Advanced Micro Devices (AMD), Nkarta (NKTX), Compass Pathways (CMPS) and Denali Therapeutics (DNLI). Company Calendar Last Earnings11/10/2026Today11/22/20269th Annual Evercore ISI HealthCONx Conference11/30/2026Citi Annual Global Healthcare Conference 202612/01/202638th Annual Healthcare Conference12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 OLMA's financial health is in the Red zone, according to TradeSmith. OLMA has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:OLMA CIK1750284 Webwww.olema.com Phone650-243-5555FaxN/AEmployees150Year Founded2007Price Target and Rating Average Price Target for Olema Pharmaceuticals$40.60 High Price Target$59.00 Low Price Target$27.00 Potential Upside/Downside+478.3%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($2.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$162.45 million Net MarginsN/A Pretax MarginN/A Return on Equity-53.67% Return on Assets-47.39% Debt Debt-to-Equity Ratio0.01 Current Ratio6.12 Quick Ratio6.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.21 per share Price / Book1.67Miscellaneous Outstanding Shares87,606,000Free Float76,603,000Market Cap$614.99 million OptionableOptionable Beta2.12 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:OLMA) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Olema Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.